Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma

Tadashi Hanafusa; Yasuhiro Yumoto; Kazuhiro Nouso; Harushige Nakatsukasa; Toru Onishi; Tatsuya Fujikawa; Mayumi Taniyama; Shinichiro Nakamura; Masayuki Uemura; Yoshitaka Takuma; Eiichiro Yumoto; Toshihiro Higashi; Takao Tsuji

doi:10.1016/S0304-3835(01)00736-4

Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma

Tadashi Hanafusa
, Yasuhiro Yumoto
, Kazuhiro Nouso
, Harushige Nakatsukasa
, Toru Onishi
, Tatsuya Fujikawa
, Mayumi Taniyama
, Shinichiro Nakamura
, Masayuki Uemura
, Yoshitaka Takuma
, Eiichiro Yumoto
, Toshihiro Higashi
, Takao Tsuji

Neutron Therapy Research Center

Research output: Contribution to journal › Article › peer-review

119 Citations (Scopus)

Abstract

Insulin-like growth factor binding protein-3 (IGFBP-3) is postulated to be a mediator of growth suppression signals. Reduced expression of the IGFBP-3 was observed in nine out of 12 human hepatocellular carcinomas (HCC) (75%). Promoter hypermethylation of the IGFBP-3 was detected in four out of 12 HCCs (33%) although mutations were not identified. The expression of IGFBP-3 was restored by the demethylating agent 5-aza-2′-deoxycytidine in HCC cell line with promoter hypermethylation (HepG2). As IGFBP-3 functions like a tumor suppressor gene, it may be used as a therapeutic target for HCC.

Original language	English
Pages (from-to)	149-158
Number of pages	10
Journal	Cancer Letters
Volume	176
Issue number	2
DOIs	https://doi.org/10.1016/S0304-3835(01)00736-4
Publication status	Published - Feb 25 2002

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Hepatocellular carcinoma
Hypermethylation
Insulin-like growth factor binding protein-3
Mannose 6-phosphate/insulin-like growth factor 2 receptor
cDNA microarray

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1016/S0304-3835(01)00736-4

Cite this

Hanafusa, T., Yumoto, Y., Nouso, K., Nakatsukasa, H., Onishi, T., Fujikawa, T., Taniyama, M., Nakamura, S., Uemura, M., Takuma, Y., Yumoto, E., Higashi, T., & Tsuji, T. (2002). Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma. Cancer Letters, 176(2), 149-158. https://doi.org/10.1016/S0304-3835(01)00736-4

Hanafusa, T, Yumoto, Y, Nouso, K, Nakatsukasa, H, Onishi, T, Fujikawa, T, Taniyama, M, Nakamura, S, Uemura, M, Takuma, Y, Yumoto, E, Higashi, T & Tsuji, T 2002, 'Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma', Cancer Letters, vol. 176, no. 2, pp. 149-158. https://doi.org/10.1016/S0304-3835(01)00736-4

@article{b35d21a92b6848d3ad3f12ed289453ff,

title = "Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma",

abstract = "Insulin-like growth factor binding protein-3 (IGFBP-3) is postulated to be a mediator of growth suppression signals. Reduced expression of the IGFBP-3 was observed in nine out of 12 human hepatocellular carcinomas (HCC) (75\%). Promoter hypermethylation of the IGFBP-3 was detected in four out of 12 HCCs (33\%) although mutations were not identified. The expression of IGFBP-3 was restored by the demethylating agent 5-aza-2′-deoxycytidine in HCC cell line with promoter hypermethylation (HepG2). As IGFBP-3 functions like a tumor suppressor gene, it may be used as a therapeutic target for HCC.",

keywords = "Hepatocellular carcinoma, Hypermethylation, Insulin-like growth factor binding protein-3, Mannose 6-phosphate/insulin-like growth factor 2 receptor, cDNA microarray",

author = "Tadashi Hanafusa and Yasuhiro Yumoto and Kazuhiro Nouso and Harushige Nakatsukasa and Toru Onishi and Tatsuya Fujikawa and Mayumi Taniyama and Shinichiro Nakamura and Masayuki Uemura and Yoshitaka Takuma and Eiichiro Yumoto and Toshihiro Higashi and Takao Tsuji",

note = "Funding Information: We are grateful to T. Mimura (Okayama Saiseikai General Hospital, Okayama, Japan), T. Kurokawa (Saiseikai Imabari Hospital, Imabari, Japan), for their support in obtaining materials and Y. Isomoto (Central Research Laboratory, Okayama University Medical School) for his technical support. We also thank Y. Iwasaki (First Department of Internal Medicine, Okayama Medical School) for his valuable suggestion to this work. This work was supported in part by grants-in-aid for Scientific Research from the Ministry of Education, Science and Culture of Japan (\#09770359, \#11770273).",

year = "2002",

month = feb,

day = "25",

doi = "10.1016/S0304-3835(01)00736-4",

language = "English",

volume = "176",

pages = "149--158",

journal = "Cancer Letters",

issn = "0304-3835",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

TY - JOUR

T1 - Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma

AU - Hanafusa, Tadashi

AU - Yumoto, Yasuhiro

AU - Nouso, Kazuhiro

AU - Nakatsukasa, Harushige

AU - Onishi, Toru

AU - Fujikawa, Tatsuya

AU - Taniyama, Mayumi

AU - Nakamura, Shinichiro

AU - Uemura, Masayuki

AU - Takuma, Yoshitaka

AU - Yumoto, Eiichiro

AU - Higashi, Toshihiro

AU - Tsuji, Takao

N1 - Funding Information: We are grateful to T. Mimura (Okayama Saiseikai General Hospital, Okayama, Japan), T. Kurokawa (Saiseikai Imabari Hospital, Imabari, Japan), for their support in obtaining materials and Y. Isomoto (Central Research Laboratory, Okayama University Medical School) for his technical support. We also thank Y. Iwasaki (First Department of Internal Medicine, Okayama Medical School) for his valuable suggestion to this work. This work was supported in part by grants-in-aid for Scientific Research from the Ministry of Education, Science and Culture of Japan (#09770359, #11770273).

PY - 2002/2/25

Y1 - 2002/2/25

N2 - Insulin-like growth factor binding protein-3 (IGFBP-3) is postulated to be a mediator of growth suppression signals. Reduced expression of the IGFBP-3 was observed in nine out of 12 human hepatocellular carcinomas (HCC) (75%). Promoter hypermethylation of the IGFBP-3 was detected in four out of 12 HCCs (33%) although mutations were not identified. The expression of IGFBP-3 was restored by the demethylating agent 5-aza-2′-deoxycytidine in HCC cell line with promoter hypermethylation (HepG2). As IGFBP-3 functions like a tumor suppressor gene, it may be used as a therapeutic target for HCC.

AB - Insulin-like growth factor binding protein-3 (IGFBP-3) is postulated to be a mediator of growth suppression signals. Reduced expression of the IGFBP-3 was observed in nine out of 12 human hepatocellular carcinomas (HCC) (75%). Promoter hypermethylation of the IGFBP-3 was detected in four out of 12 HCCs (33%) although mutations were not identified. The expression of IGFBP-3 was restored by the demethylating agent 5-aza-2′-deoxycytidine in HCC cell line with promoter hypermethylation (HepG2). As IGFBP-3 functions like a tumor suppressor gene, it may be used as a therapeutic target for HCC.

KW - Hepatocellular carcinoma

KW - Hypermethylation

KW - Insulin-like growth factor binding protein-3

KW - Mannose 6-phosphate/insulin-like growth factor 2 receptor

KW - cDNA microarray

UR - https://www.scopus.com/pages/publications/18244401685

UR - https://www.scopus.com/pages/publications/18244401685#tab=citedBy

U2 - 10.1016/S0304-3835(01)00736-4

DO - 10.1016/S0304-3835(01)00736-4

M3 - Article

C2 - 11804742

AN - SCOPUS:18244401685

SN - 0304-3835

VL - 176

SP - 149

EP - 158

JO - Cancer Letters

JF - Cancer Letters

IS - 2

ER -

Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma

Abstract

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this